[A case of giant advanced breast cancer responding remarkably to chemo-endocrine therapy chiefly with doxifluridine].
A 68-year-old woman presented with advanced ulcerative breast cancer of the precordium; edema of the face, cervix and bilateral upper extremities; dyspnea from carcinomatous pleurisy; and multiple bone metastases, which suggested a terminal state. Her general condition improved with symptomatic therapies; thus, doxifluridine (5'-DFUR) and an endocrine therapeutic drug were given to reduce the primary focus, eliminate the edemas and decrease the plural effusion. When the tumor markers increased again, CEFT therapy [cyclophosphamide (CPA), epirubicin (epi-ADM), 5-fluorouracil (5-FU) and tamoxifen (TAM)] was conducted. This resulted in no adverse drug reaction, further reduction of the primary focus, and extremely improved Performance status (PS). The patient was discharged on 5'-DFUR and TAM therapy, which resulted in scarring of the ulcer, normalization of tumor marker levels, disappearance of the pleural effusion, and a reduction of metastatic bone foci. The findings suggest 5'-DFUR and endocrine therapeutic drugs can have a favorable clinical effect without impacting QOL and should be employed in patients with advanced cancer and poor general condition.
Fujitake
S
S
Dept. of Surgery, Meitetsu Hospital.
Maeda
Y
Y
Shimizu
M
M
Nozaki
H
H
Tohyama
M
M
Kataoka
S
S
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000737:chemistry / Q000188:drug therapy* / Q000556:secondary; D003520:Cyclophosphamide / Q000008:administration & dosage; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage*; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D016066:Pleural Effusion, Malignant / Q000188:drug therapy; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D013629:Tamoxifen / Q000008:administration & dosage
D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D005467:Floxuridine; D013629:Tamoxifen; D015251:Epirubicin; D003520:Cyclophosphamide; D005472:Fluorouracil; C025034:doxifluridine